Nuvectis Pharma, Inc. (NVCT) · Nov 4, 2026 · Earnings

Nuvectis earnings miss on license costs as cash runway reaches 2029

Miss — GAAP EPS $(1.02) vs approximately $(0.22) consensus; $20.0M license payment included

Nuvectis’ third-quarter earnings missed consensus because of upfront license costs, while $140.7 million in cash funds its next clinical and FDA milestones.

Nuvectis is transitioning from a small early-stage oncology company into a late-stage clinical platform built around newly licensed assets NXP100 and NXP200, backed by a July financing that was already known before this report. The filing mainly confirms that transition is funded, while adding clinical updates and near-term regulatory milestones.

The headline earnings result is a clear miss, but the comparison is distorted by deal accounting. GAAP loss per share was $1.02 versus a published consensus loss of roughly $0.22, making this a formal earnings miss. The company says the quarter included a $20.0 million upfront payment for the NXP100/NXP200 license and $1.8 million in NXP900 milestones, so the reported loss does not represent the underlying quarterly development burn alone.

FigureQ3 2026Q3 2025Consensus
Diluted EPS (Statement of Operations)$(1.02)$(0.44)$(0.22)
Net loss (Statement of Operations)$(30.1M)$(7.5M)
R&D expense (Statement of Operations)$27.4M$5.8M
Cash and equivalents (Balance Sheet)$140.7M

The balance sheet is the more important business update. Cash rose to $140.7 million after the follow-on offering and ATM activity, giving Nuvectis substantially more capacity to execute its expanded pipeline rather than immediately return to the capital markets. The company says that cash is expected to fund operations into the second half of 2029.

The clinical story advances, but this is still a milestone setup rather than a proof point. NXP100 has China approval in one PNH population, while the U.S. path remains dependent on ongoing FDA discussions; NXP200's reported Phase 1b activity is encouraging but comes from a small 27-patient dataset. The filing points to an FDA update and U.S. IND submissions by year-end, which are the next events capable of converting the newly funded platform into concrete regulatory progress. 〔0〕 〔1〕

Bottom line: This is a formal earnings miss, but mostly because Nuvectis paid for the pipeline it is now funded to develop. The business story is modestly better on liquidity and execution, though the key U.S. regulatory steps remain ahead rather than delivered.

What to watch next

FDA update and U.S. IND submissions expected by year-end

Original filing on SEC EDGAR

Nuvectis earnings miss on license costs as cash runway reaches 2029 | NVCT Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.